Further studies are ongoing in our laboratory to formally and definitively prove that SETD8 overexpression could, indeed, be a biomarker, easily investigated by immunohistochemistry, for predicting response of glioblastomas to UNC0379+adavosertib combination. The gene discussed is KMT5A; the disease is glioblastoma.